Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Tg Therapeutics (TGTX) over the last 16 years, with Dec 2024 value amounting to $128.5 million.

  • Tg Therapeutics' Cash from Financing Activities fell 158.19% to -$78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$96.9 million, marking a year-over-year decrease of 171.96%. This contributed to the annual value of $128.5 million for FY2024, which is 76.78% up from last year.
  • Per Tg Therapeutics' latest filing, its Cash from Financing Activities stood at $128.5 million for FY2024, which was up 76.78% from $72.7 million recorded in FY2023.
  • Tg Therapeutics' Cash from Financing Activities' 5-year high stood at $679.8 million during FY2020, with a 5-year trough of -$391,000 in FY2022.
  • In the last 3 years, Tg Therapeutics' Cash from Financing Activities had a median value of $72.7 million in 2023 and averaged $66.9 million.
  • As far as peak fluctuations go, Tg Therapeutics' Cash from Financing Activities slumped by 100.94% in 2022, and later spiked by 18,694.63% in 2023.
  • Over the past 5 years, Tg Therapeutics' Cash from Financing Activities (Yearly) stood at $679.8 million in 2020, then plummeted by 93.91% to $41.4 million in 2021, then plummeted by 100.94% to -$391,000 in 2022, then surged by 18,694.63% to $72.7 million in 2023, then soared by 76.78% to $128.5 million in 2024.